F-Box only protein 7 gene in Parkinsonian-Pyramidal disease

Archives of Neurology

Volumn 70, Issue 1, 2013, Pages 20-24

  Deng, Hao ^a   Liang, Hui ^a   Jankovic, Joseph ^b  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE 5; CYCLIN DEPENDENT KINASE 6; F BOX ONLY PROTEIN 7; F BOX PROTEIN; UBIQUITIN PROTEIN LIGASE; UNCLASSIFIED DRUG; FBXO7 PROTEIN, HUMAN;

ATP13A2 GENE; AUTOSOMAL RECESSIVE INHERITANCE; CHROMOSOMAL LOCALIZATION; CLINICAL FEATURE; DJ 1 GENE; FAMILY HISTORY; FBXO7 GENE; GENE; GENE FUNCTION; GENE MUTATION; GENETIC ASSOCIATION; HETEROZYGOTE; HOMOZYGOTE; HUMAN; MUTATIONAL ANALYSIS; NEUROPATHOLOGY; NONHUMAN; ONSET AGE; PARKIN GENE; PARKINSON DISEASE; PARKINSONIAN PYRAMIDAL DISEASE; PARKINSONISM; PINK1 GENE; PLA2G6 GENE; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; REVIEW; SPASTICITY; UBIQUITINATION; BLEPHAROSPASM; GENETICS; GLOBUS PALLIDUS; MUTATION; GENE LOCUS; LINKAGE ANALYSIS; NUCLEOTIDE SEQUENCE; PARK15 GENE; PATHOGENESIS;

BLEPHAROSPASM; F-BOX PROTEINS; GLOBUS PALLIDUS; HUMANS; MUTATION; PARKINSON DISEASE, SECONDARY;

MLCS; MLOWN;

EID: 84872590599     PISSN: 00039942     EISSN: 15383687     Source Type: Journal    
DOI: 10.1001/jamaneurol.2013.572     Document Type: Review

References (32)

1. Yang YX, Wood NW, Latchman DS. Molecular basis of Parkinson's disease. Neuroreport. 2009;20(2):150-156.
2. Warner TT, Schapira AH. Genetic and environmental factors in the cause of Parkinson's disease. Ann Neurol. 2003;53(suppl 3):S16-S23, discussion S23-S25.
3. International Parkinson Disease Genomics Consortium; Nalls MA, Plagnol V, Hernandez DG, et al. Imputation of sequence variants for identification of genetic risks for Parkinson's disease: a meta-analysis of genome-wide association studies. Lancet. 2011;377(9766):641-649.
4. Simón-Sánchez J, Schulte C, Bras JM, et al. Genome-wide association study reveals genetic risk underlying Parkinson's disease. Nat Genet. 2009;41(12): 1308-1312.
5. Vilariño-Güell C, Wider C, Ross OA, et al. VPS35 mutations in Parkinson disease. Am J Hum Genet. 2011;89(1):162-167.
6. Chartier-Harlin MC, Dachsel JC, Vilariño-Güell C, et al. Translation initiator EIF4G1 mutations in familial Parkinson disease. Am J Hum Genet. 2011;89(3):398-406.
7. Shulman JM, De Jager PL, Feany MB. Parkinson's disease: genetics and pathogenesis. Annu Rev Pathol. 2011;6:193-222.
8. Martin I, Dawson VL, Dawson TM. Recent advances in the genetics of Parkinson's disease. Annu Rev Genomics Hum Genet. 2011;12:301-325.
9. Jankovic J. Parkinson's disease: clinical features and diagnosis. J Neurol Neurosurg Psychiatry. 2008;79(4):368-376. (Pubitemid 351441488)
10. Shojaee S, Sina F, Banihosseini SS, et al. Genome-wide linkage analysis of a Parkinsonian-pyramidal syndrome pedigree by 500 K SNP arrays. Am J Hum Genet. 2008;82(6):1375-1384.
11. Ilyin GP, Rialland M, Pigeon C, Guguen-Guillouzo C. cDNA cloning and expression analysis of new members of themammalian F-box protein family. Genomics. 2000;67(1):40-47. (Pubitemid 30471119)
12. Davison C. Pallido-pyramidal disease. J Neuropathol Exp Neurol. 1954;13(1):50-59.
13. Kalita J, Misra UK, Das BK. Sporadic variety of pallido-pyramidal syndrome. Neurol India. 2003;51(3):383-384. (Pubitemid 38016287)
14. Horowitz G, Greenberg J. Pallido-pyramidal syndrome treated with levodopa. J Neurol Neurosurg Psychiatry. 1975;38(3):238-240.
15. Horstink MW, Dekker MC, Montagna P, Bonifati V, van De Warrenburg BP. Pallidopyramidal disease: a misnomer? Mov Disord. 2010;25(9):1109-1115.
16. Panagariya A, Sharma B, Dev A. Pallido-pyramidal syndrome: a rare entity. Indian J Med Sci. 2007;61(3):156-157.
17. Hampshire DJ, Roberts E, Crow Y, et al. Kufor-Rakeb syndrome, pallidopyramidal degeneration with supranuclear upgaze paresis and dementia, maps to 1p36. J Med Genet. 2001;38(10):680-682. (Pubitemid 32946789)
18. Bonifati V. Autosomal recessive parkinsonism. Parkinsonism Relat Disord. 2012; 18(suppl 1):S4-S6.
19. Schneider SA, Bhatia KP, Hardy J. Complicated recessive dystonia parkinsonism syndromes. Mov Disord. 2009;24(4):490-499.
20. Dusek P, Jankovic J, Le W. Iron dysregulation in movement disorders. Neurobiol Dis. 2012;46(1):1-18.
21. Di Fonzo A, Dekker MC, Montagna P, et al. FBXO7 mutations cause autosomal recessive, early-onset parkinsonian-pyramidal syndrome. Neurology. 2009; 72(3):240-245.
22. Zhao T, De Graaff E, Breedveld GJ, et al. Loss of nuclear activity of the FBXO7 protein in patients with parkinsonian-pyramidal syndrome (PARK15). PLoS One. 2011;6(2):e16983.
23. Paisán-Ruiz C, Guevara R, Federoff M, et al. Early-onset L-dopa-responsive parkinsonism with pyramidal signs due to ATP13A2, PLA2G6, FBXO7 and spatacsin mutations. Mov Disord. 2010;25(12):1791-1800.
24. Luo LZ, Xu Q, Guo JF, et al. FBXO7 gene mutations may be rare in Chinese earlyonset Parkinsonism patients. Neurosci Lett. 2010;482(2):86-89.
25. Hsu JM, Lee YC, Yu CT, Huang CY. Fbx7 functions in the SCF complex regulating Cdk1-cyclin B-phosphorylated hepatoma up-regulated protein (HURP) proteolysis by a proline-rich region. J Biol Chem. 2004;279(31):32592-32602.
26. Chang YF, Cheng CM, Chang LK, Jong YJ, Yuo CY. The F-box protein Fbxo7 interacts with human inhibitor of apoptosis protein cIAP1 and promotes cIAP1 ubiquitination. Biochem Biophys Res Commun. 2006;342(4):1022-1026.
27. Kirk R, Laman H, Knowles PP, et al. Structure of a conserved dimerization domain within the F-box protein Fbxo7 and the PI31 proteasome inhibitor. J Biol Chem. 2008;283(32):22325-22335.
28. Inzelberg R, Jankovic J. Are Parkinson disease patients protected from some but not all cancers? Neurology. 2007;69(15):1542-1550. (Pubitemid 47537862)
29. Zaiss DM, Standera S, Kloetzel PM, Sijts AJ. PI31 is a modulator of proteasome formation and antigen processing. Proc Natl Acad Sci U S A. 2002;99(22): 14344-14349. (Pubitemid 35257674)
30. Laman H. Fbxo7 gets proactive with cyclin D/cdk6. Cell Cycle. 2006;5(3):279-282. (Pubitemid 43213498)
31. Smith PD, O'Hare MJ, Park DS. CDKs: taking on a role as mediators of dopaminergic loss in Parkinson's disease. Trends Mol Med. 2004;10(9):445-451. (Pubitemid 39209211)
32. Cook C, Petrucelli L. A critical evaluation of the ubiquitin-proteasome system in Parkinson's disease. Biochim Biophys Acta. 2009;1792(7):664-675.